Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Launched by BRISTOL-MYERS SQUIBB · Apr 8, 2014
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Inclusion Criteria:
- • Subjects with advanced/metastatic Colorectal Cancer(CRC) who have failed or been intolerant to both irinotecan- and oxaliplatin- based regimens
- • Subjects with advanced/metastatic Squamous cell carcinoma of the head and neck (SCCHN) who are without options for curative treatment
- • Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- • Men and women 18 and older
- • Women of childbearing potential (WOCBP) and men must use highly effective methods of contraception
- • Eastern Cooperative Oncology Group (ECOG) of 0 or 1
- • Subjects must have a life expectancy of at least 3 months
- Exclusion Criteria:
- • Active or progressing brain metastases
- • Other concomitant malignancies (with some exceptions per protocol)
- • Nasopharyngeal carcinoma
- • Active or history of autoimmune disease
- • Positive test for Human Immunodeficiency Virus (HIV) 1\&2 or known AIDS
- • History of any hepatitis (A,B or C)
- • Known current drug or alcohol abuse
- • Active Tuberculosis (TB)
- • Use of anti-cancer treatments within 28 days
- • Prior therapy with anti-CD137 antibody
- • Other protocol defined inclusion/exclusion criteria could apply
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Chicago, Illinois, United States
Stanford, California, United States
New York, New York, United States
Boston, Massachusetts, United States
Pittsburgh, Pennsylvania, United States
Portland, Oregon, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials